These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
590 related articles for article (PubMed ID: 33979868)
1. The Potential Role of Psychedelic Drugs in Mental Health Care of the Future. Gründer G; Jungaberle H Pharmacopsychiatry; 2021 Jul; 54(4):191-199. PubMed ID: 33979868 [TBL] [Abstract][Full Text] [Related]
2. Psychedelics: Alternative and Potential Therapeutic Options for Treating Mood and Anxiety Disorders. Lowe H; Toyang N; Steele B; Grant J; Ali A; Gordon L; Ngwa W Molecules; 2022 Apr; 27(8):. PubMed ID: 35458717 [TBL] [Abstract][Full Text] [Related]
4. United States National Institutes of Health grant funding for psychedelic-assisted therapy clinical trials from 2006-2020. Barnett BS; Parker SE; Weleff J Int J Drug Policy; 2022 Jan; 99():103473. PubMed ID: 34624734 [TBL] [Abstract][Full Text] [Related]
5. Dosing Psychedelics and MDMA. Liechti ME; Holze F Curr Top Behav Neurosci; 2022; 56():3-21. PubMed ID: 34734392 [TBL] [Abstract][Full Text] [Related]
7. Medicinal psychedelics for mental health and addiction: Advancing research of an emerging paradigm. Perkins D; Sarris J; Rossell S; Bonomo Y; Forbes D; Davey C; Hoyer D; Loo C; Murray G; Hood S; Schubert V; Galvão-Coelho NL; O'Donnell M; Carter O; Liknaitzky P; Williams M; Siskind D; Penington D; Berk M; Castle D Aust N Z J Psychiatry; 2021 Dec; 55(12):1127-1133. PubMed ID: 33745287 [TBL] [Abstract][Full Text] [Related]
8. Analysis of recreational psychedelic substance use experiences classified by substance. Hase A; Erdmann M; Limbach V; Hasler G Psychopharmacology (Berl); 2022 Feb; 239(2):643-659. PubMed ID: 35031816 [TBL] [Abstract][Full Text] [Related]
9. [Psychotherapy with Adjuvant use of Serotonergic Psychoactive Substances: Possibilities and Challenges]. Majić T; Jungaberle H; Schmidt TT; Zeuch A; Hermle L; Gallinat J Fortschr Neurol Psychiatr; 2017 Jul; 85(7):383-392. PubMed ID: 28768346 [No Abstract] [Full Text] [Related]
10. The Pharmacology and Clinical Applications of Psychedelic Medicines Within Midwifery Practice. Stein CA; Penn A; Van Hope S; Dorsen CG; Mangini M J Midwifery Womens Health; 2022 May; 67(3):373-383. PubMed ID: 35522087 [TBL] [Abstract][Full Text] [Related]
11. Psychedelic Psychiatry and the Consult-Liaison Psychiatrist: A Primer. Barnett BS; Greer GR J Acad Consult Liaison Psychiatry; 2021; 62(4):460-471. PubMed ID: 34210406 [TBL] [Abstract][Full Text] [Related]
12. The changing outlook of psychedelic drugs: The importance of risk assessment and occupational exposure limits. Videira NB; Nair V; Paquet V; Calhoun D J Appl Toxicol; 2024 Feb; 44(2):216-234. PubMed ID: 37646119 [TBL] [Abstract][Full Text] [Related]
13. Psychedelic renaissance: Revitalized potential therapies for psychiatric disorders. Rhee TG; Davoudian PA; Sanacora G; Wilkinson ST Drug Discov Today; 2023 Dec; 28(12):103818. PubMed ID: 37925136 [TBL] [Abstract][Full Text] [Related]
15. The need for establishing best practices and gold standards in psychedelic medicine. Feduccia A; Agin-Liebes G; Price CM; Grinsell N; Paradise S; Rabin DM J Affect Disord; 2023 Jul; 332():47-54. PubMed ID: 37003433 [TBL] [Abstract][Full Text] [Related]
16. Psychedelics for treatment resistant depression: are they game changers? Kalfas M; Taylor RH; Tsapekos D; Young AH Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195 [TBL] [Abstract][Full Text] [Related]
17. Cessation and reduction in alcohol consumption and misuse after psychedelic use. Garcia-Romeu A; Davis AK; Erowid F; Erowid E; Griffiths RR; Johnson MW J Psychopharmacol; 2019 Sep; 33(9):1088-1101. PubMed ID: 31084460 [TBL] [Abstract][Full Text] [Related]
18. Psychedelic Therapy: A Primer for Primary Care Clinicians-Historical Perspective and Overview. Tabaac BJ; Shinozuka K; Arenas A; Beutler BD; Cherian K; Evans VD; Fasano C; Muir OS Am J Ther; 2024 Mar-Apr 01; 31(2):e97-e103. PubMed ID: 38518266 [TBL] [Abstract][Full Text] [Related]